Core Insights - Affirm Holdings Inc. is experiencing significant stock pressure, down 15% year-to-date due to sector-wide challenges and company-specific issues [1] - The company's Momentum score in Benzinga's Edge Stock Rankings has sharply declined from 72.68 to 21.46, reflecting the stock's recent downturn [2] Company Performance - Affirm's shares fell by 3.92% on Thursday, closing at $62.80, and dropped another 1.82% overnight, indicating a negative trend [4] - The stock is rated high on Growth but performs poorly on Value and Momentum, with unfavorable price trends across short, medium, and long-term periods [4] Market Sentiment - The decline in Affirm's stock was exacerbated by a short report from activist short-seller Kerrisdale Capital, which criticized the company's credit fundamentals and reliance on financially unstable consumers [3]

Core Viewpoint - Gold prices are experiencing a significant rally, nearing the $5,600 per ounce mark, driven by geopolitical tensions and the Federal Reserve's decision to maintain interest rates [1][2][3]. Group 1: Gold Price Movement - Gold has gained over 10% in just four sessions, reaching an all-time high of $5,595.44 [1][5]. - As of the latest check, gold spot is trading at $5,506.47, with technical resistance identified between $5,525 and $5,600 [5]. Group 2: ETF Performance - Five key gold ETFs have entered the top 10th percentile of momentum scores, indicating strong relative price strength and volatility [1][2]. - The ETFs include Goldman Sachs Physical Gold ETF, SPDR Gold Trust, SPDR Gold MiniShares Trust, iShares Gold Trust, and VanEck Merk Gold ETF, all showing positive momentum across three critical timeframes [2]. Group 3: Market Dynamics - The Federal Reserve's decision to keep interest rates unchanged at 3.50%–3.75% is interpreted as a sign of prolonged monetary support, reducing the opportunity cost of holding gold [2][3]. - Investors are increasingly moving towards tangible assets like gold due to rising geopolitical uncertainties, particularly tensions between the U.S. and Iran [3][4]. Group 4: Investor Outlook - The short-term outlook for gold is positive, with an upward trend observed over the last couple of months [5]. - The medium-term trend remains positive, sustained over the last couple of quarters, while the long-term outlook shows a sustained upward movement over the past year [5].

Core Insights - CRISPR Therapeutics AG is facing renewed pressure due to insider sales, slow revenue growth, and weak product adoption [1] - The company's Momentum score has significantly declined, indicating a drop in investor confidence [2] Revenue Performance - The company's revenue for the third quarter was reported at $890,000, which is substantially below the consensus estimate of $8.06 million [4] - This disappointing revenue performance has contributed to a loss of confidence among investors [4] Insider Activity - CEO Samarth Kulkarni sold over 90,000 shares in a pre-arranged transaction, which has raised concerns among investors despite him retaining approximately 85,000 shares [3] - The timing and scale of these sales have unsettled the market, further impacting the stock's performance [3] Stock Performance - CRISPR Therapeutics AG's stock has dropped over 10% in the past week, leading to a decline in its Momentum score from 76.81 to 50.97 [2] - The stock is currently ranked poorly in Benzinga's Edge Stock Rankings, reflecting unfavorable price trends in both the short and medium terms [4]

Core Viewpoint - United Community Banks, Inc. (UCB) is highlighted as a stock with a buy rank and strong momentum characteristics for investors to consider [1] Summary by Category Company Performance - United Community Banks has a Zacks Rank of 1, indicating strong performance [1] - The Zacks Consensus Estimate for its current year earnings has increased by 0.7% over the last 60 days [1] - The company's shares have gained 14.1% over the last three months, contrasting with the S&P 500's decline of 4.3% [1] Momentum Characteristics - United Community Banks possesses a Momentum Score of A, reflecting its strong momentum in the market [1]

Core Viewpoint - Moderna Inc. is experiencing a resurgence in stock momentum after a significant decline since its peak in 2021, driven by improved financial outlook and investor sentiment [1][4]. Group 1: Stock Performance - The stock has seen a 91.87% decline from its all-time high in 2021, but has recently gained 76% from its November 2025 lows [1][3]. - The Momentum score in Benzinga's Edge Stock Rankings has increased from 22.5 to 74.61 in just one week, indicating a strong turnaround in investor sentiment [2][3]. - Shares have climbed 31.7% in the past month and an additional 14.8% over the past week [3]. Group 2: Financial Outlook - Moderna's full-year 2025 revenue is projected at $1.9 billion, exceeding previous estimates by approximately $100 million [4]. - The company has reduced its GAAP operating expense forecast by about $200 million for the year, improving its cost structure [4]. - The projected year-end cash balance has been increased to $8.1 billion, contributing to positive investor sentiment [4]. Group 3: Recent Trading Activity - On a recent trading day, shares of Moderna closed down 3.01% at $39.36 but were up 0.66% overnight [5]. - The stock maintains a favorable price trend across short, medium, and long-term time frames in Benzinga's Edge Stock Rankings [5].

Core Insights - Oscar Health Inc. has experienced a significant decline in its Momentum score, dropping from 62.07 to 13.22 within a week, indicating a loss of stock strength relative to peers [3][4] - The company's stock has only increased by 7% year-to-date, and it has faced a 19.14% decline over the past month, reflecting broader pressures on health insurance stocks due to uncertainties surrounding the Affordable Care Act subsidies [1][3] - Analysts predict a potential turnaround for Oscar Health in 2026, with an upgrade to "Overweight" by Piper Sandler and a price target of $25, suggesting a 72% upside from current levels [4] Company Performance - Oscar Health's shares closed at $14.53, down 2.55% on a recent Monday, and the stock is performing poorly in Benzinga's Edge Stock Rankings, showing unfavorable trends across short, medium, and long-term periods [5] - The stock has exhibited increased volatility without clear directional strength, complicating momentum modeling [4]

Core Insights - Three stocks with strong buy rankings and momentum characteristics are highlighted for investors: Charles Schwab, Texas Capital Bancshares, and Southern First Bancshares [1][2][3][4] Company Summaries - **Charles Schwab (SCHW)**: - Zacks Rank: 1 (Strong Buy) - Current year earnings estimate increased by 6.5% over the last 60 days - Share price increased by 19.4% over the last three months, outperforming the S&P 500's 15.2% gain - Momentum Score: A [1][2] - **Texas Capital Bancshares (TCBI)**: - Zacks Rank: 1 (Strong Buy) - Current year earnings estimate increased by 8.2% over the last 60 days - Share price increased by 30% over the last three months, significantly outperforming the S&P 500's 15.2% gain - Momentum Score: A [2][3] - **Southern First Bancshares (SFST)**: - Zacks Rank: 1 (Strong Buy) - Current year earnings estimate increased by 14.2% over the last 60 days - Share price increased by 33.3% over the last three months, also outperforming the S&P 500's 15.2% gain - Momentum Score: A [3][4]